Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

866 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, Okami J, Sakakura N, Kubota K, Takamochi K, Atagi S, Tsuboi M, Oizumi S, Ikeda N, Ohde Y, Ntambwe I, Mahmood J, Cai J, Tanaka F. Mitsudomi T, et al. Among authors: sugawara s. Cancer Sci. 2024 Feb;115(2):540-554. doi: 10.1111/cas.16030. Epub 2023 Dec 14. Cancer Sci. 2024. PMID: 38098261 Free PMC article. Clinical Trial.
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group; Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Kudoh S, et al. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12. Am J Respir Crit Care Med. 2008. PMID: 18337594
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T. Inoue A, et al. Among authors: sugawara s. Ann Oncol. 2010 Apr;21(4):800-803. doi: 10.1093/annonc/mdp384. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825887 Free article. Clinical Trial.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: sugawara s. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma.
Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, Yamamoto M. Inoue D, et al. Among authors: sugawara s. Cancer Sci. 2012 Apr;103(4):760-6. doi: 10.1111/j.1349-7006.2012.02216.x. Epub 2012 Feb 21. Cancer Sci. 2012. PMID: 22320446 Free PMC article.
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Oizumi S, et al. Among authors: sugawara s. Oncologist. 2012;17(6):863-70. doi: 10.1634/theoncologist.2011-0426. Epub 2012 May 11. Oncologist. 2012. PMID: 22581822 Free PMC article. Clinical Trial.
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Inoue A, et al. Among authors: sugawara s. Ann Oncol. 2013 Jan;24(1):54-9. doi: 10.1093/annonc/mds214. Epub 2012 Sep 11. Ann Oncol. 2013. PMID: 22967997 Free article. Clinical Trial.
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Harada T, et al. Among authors: sugawara s. Oncologist. 2013;18(4):439-45. doi: 10.1634/theoncologist.2012-0308. Epub 2013 Feb 26. Oncologist. 2013. PMID: 23442308 Free PMC article. Clinical Trial.
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Kawashima Y, et al. Among authors: sugawara s. Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28. Respir Investig. 2014. PMID: 24853020 Clinical Trial.
866 results